Pfizer Sets Record; Becomes First $100-Bn Company in Bio/Pharma Industry
By

By
Pfizer became the first $100-billion company in the industry in 2022 on the strength of its COVID-19 vaccine and COVID-19 drug. Will its record-breaking results hold in 2023, and how will non-COVID products perform? 

Top 10 Key Trends in New Drug Approvals: Small Molecules & Biologics
By

By
DCAT Value Chain Insights provides its Top 10 Watchlist in new drug approvals, including the mix between small molecules & biologics, small & large companies, and blockbuster contenders.

Manufacturing and Supply: The Impact Factors for 2023
By

By
What are key issues impacting bio/pharma manufacturing and supply in 2023? DCAT Value Chain Insights takes an inside look at what is on the industry’s radar.

Global Spending & Demand for Medicines: Up or Down?
By

By
Global demand & spending for medicines will increase to $1.9 trillion by 2027. COVID-19 vaccines will continue to be a growth driver, but what else is in play?

The Year Ahead: What’s on the Minds of CEOs?
By

By
Economic uncertainty, supply chain, talent management, and risk mitigation were key issues cited by CEOs in PwC’s Global CEO survey, released at the World Economic Forum in Davos, Switzerland. What are key takeaways from a study of 4,400 CEOs?

Big Pharma’s Growth Initiatives in 2023: Part 2
By

By
More coverage of the J.P. Morgan Annual Healthcare Conference in San Francisco earlier this month, where bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives. What are more highlights?

The CDMO/CMO Report: The Year Ahead in Bio/Pharma Outsourcing
By

By
What can the markets for bio/pharmaceutical outsourcing expect in 2023? DCAT Value Chain Insights examines key trends and highlights in major manufacturing segments: API and drug-product manufacturing. 

Big Pharma Strategies and Growth Initiatives: What’s In Store for 2023
By

By
At the J.P. Morgan Annual Healthcare Conference in San Francisco this week, bio/pharma industry executives highlighted their companies’ strategies and key growth initiatives.

The Bio/Pharma Industry’s Watchlist for 2023
By

By
What are the top 10 items on the bio/pharma industry’s watchlist for 2023? To continued inflationary pressures, a looming global recession, to moderating global bio/pharma industry growth, DCAT Value Chain Insights examines what is on the industry’s radar. 

New Drug Approvals in 2022: Making the Mark
By

By
There were 37 new molecular entities and therapeutic biologics approved in 2022 by the FDA, significantly down from the 50 new drugs approved in 2021. What were the winners in small molecules and biologics and large and small companies?